An open label phase II trial of CEP-701 [lestaurtinib] in older patients with acute myeloid leukaemia not considered fit for intensive chemotherapy

Trial Profile

An open label phase II trial of CEP-701 [lestaurtinib] in older patients with acute myeloid leukaemia not considered fit for intensive chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Lestaurtinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Sponsors Cephalon
  • Most Recent Events

    • 03 Jul 2010 Status changed from active, no longer recruiting to completed as reported by United Kingdom Clinical Research Network record.
    • 19 Dec 2009 Additional lead centre, trial locations, trial investigator (Alan Burnett) and Cephalon as trial sponsor added as reported by United Kingdom Clinical Research Network record.
    • 19 Dec 2009 New source identified and integrated (United Kingdom Clinical Research Network).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top